“Latest Stem Cells News”

A growing trend in USA takes some desperate Americans, unhappy with the US law, travel far away up to China and Thailand, for treatments they hope will help them.

http://www.beike.ch/images/stories/Image/video/nniwilliamschina070830.flv#/20071220230_To_China_for_stem_cell_treatment_nniwilliamschina070830.flv http://www.beike.ch/images/stories/Image/video/BeikeOnCNN.flv#/Europe_su_CNN_BeikeOnCNN.flv

from NBC , CNN

Incoming search terms:

After seeing the fastest development worldwide in stem cell research during the past 10 years, China is “on the verge of achieving a breakthrough”, says a top scientist in the field.
Zhou Qi, chief scientist with the stem cell research project at the Chinese Academy of Sciences (CAS), spoke after the academy chose his area of expertise for significant attention.

He said Chinese scientists are expecting a major scientific breakthrough to be made within the next decade.
“We are now close to the day when we will be able to hail a breakthrough in this important technology,” Zhou told China Daily during an exclusive interview.

He said China has already succeeded in creating a “stem cell line up to clinical standards“, which signifies a major stride toward clinical treatment.
“China needs five to 10 years to shift from basic research to clinical application and another 10 years to realize large-scale clinical application,” he said.

“If there are any science projects that could win China a Nobel Prize during the next 10 years, the most likely candidate is its stem cell research.”
Going forward, the priority will be to focus on stem cell regulation, core mechanisms for stem-cell therapies and standardized applications of stem cells, Zhou said.

Incoming search terms:

Chinese researchers have become the world’s fifth most prolific contributors to peer-reviewed scientific literature on Regenerative Medicine (RM), according to an international study published on Friday (…)
Regenerative Medicine is an emerging interdisciplinary field of research and clinical applications focused on the repair, replacement or regeneration of cells, tissues, or organs, which uses a combination of approaches including gene therapy, stem cell transplantation, tissue engineering, and the reprogramming of cell and tissue types.

But as the stem cell research develops fast in recent years, RM becomes more and more dependent on this side, and shared some ethic criticism against stem cell research since it involves the usage of human embryos.

Incoming search terms:

Warnings are being issued by experts of the dangers of medical tourism saying that unproven stem cell therapy overseas could leave patients worse off.

Signing up for stem cell therapy is worth the risk for many people who are suffering with conditions like spinal injury, multiple sclerosis, motor neuron or Parkinson’s disease.

A medical journal reported earlier this year that an Israeli teenager developed brain tumors after experimental injections at a Russian clinic.

There are alternate reports also of patients contracting meningitis after treatments in China.

A handbook will be released by the Australian Stem Cell Centre to help patients analyze radial stem cell treatments abroad.

Experts, however, are warning patients against taking the risk with radical treatments abroad.

The Australian Stem Cell Centre Clinical adviser Dr Kirsten Herbert says that three patients contracted meningitis after stem cell treatment in China because of spinal cord injuries.

He also adds that cancer too is a possible side-effect although the likelihood is very rare.

It is important to not demoralize people who are seeking these cures but they must be helped in finding the right advice.

from http://topnews.us/content/28514-warning-issued-against-stem-cell-tourism-experts

Incoming search terms:

Stem-cell firm BioTime said this week that it will open a subsidiary in China called BioTime Asia to expand its stem cell therapeutics and research tools to the Asian market.

BioTime Asia will be based at the Nanshan Memorial Medical Institute, or NSMMI, and will clinically develop and market therapeutic stem cell products in China and market stem cell research products in China and other Asian countries (…)

BioTime and its US research tools subsidiary, Embryome Sciences, will license the rights to certain stem cell technology to BioTime Asia, and will sell the Chinese subsidiary stem cell products for therapeutic use and for resale as research products, BioTime said. Under the arrangement, BioTime Asia will license back to BioTime any new technology it might develop or acquire for use outside of China (…)

from http://www.genomeweb.com/print/924594

Incoming search terms:

The hardship’s focus is on pilot studies conducted in China. Sean Hu, CEO and Chair of Shenzhen Beike Biotechnologies Co. Ltd. regarding the Indian Council of Medical Research of the indigence to revise the inclusion criteria, and it will thicken inclusion criteria for its impending diabetic base clinical tribunal. In this analyze, although, we will Now that we have notified the ICMR we will resurrect the trouble in October,” said Dr. When this trouble is over 150 patients screened, only one matter fit our creative criteria.” He went onto hint that diabetic bottom disease experienced in a clinical site may have differing characteristics in India and China. Fortis notified the implications of the cram.

Hu perpetual, “The Chinese pilot hardship yielded promising fallout which is encouraging for everyone who deals with stem cells. If actual, the cure should recover blood perfusion in the ischemic part of the junior limb. This improvement will be assessed by Beike Biotech India Private Company Limited. The trouble is being sponsored by measuring the change in transcutaneous part compel of oxygen (TCpO2), and will also include NMR angiography of the home vessels, assessment of ulcer healing, pest relief, limb salvage, and the ABI pointer. Diabetic foot disease is a grim announce in India. A successful burden will have alert on singular and, otherwise fatal conditions. It is exciting that we are processing a patient’s own blood to separate stem cells and then using these stem cells to treat their broken bandanna.”

The clinical testing is officially posh, “A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.” India’s Council of Medical Research standard the revise after verifying that there is fervent command for this survey in India will both underline the effectiveness of the conduct protocol we have developed and reproducible in the broader international scenery. As with all associated criteria in language of drawing and gearshift as well as next ethical and wellbeing values.

“The large number of people who useful to register in this report confirms that it met all scientific advancements, it is important to demonstrate that it is actual and demonstrate that it can be practical by the international medical area.”

The preceding survey as bottom ulcers. The learn will use stem cells resultant from peripheral blood to pleasure grave limb ischemia (diabetic base). Current remedial of diabetic base ulcers involves intensive wound management, expose reduction and lengthy rehabilitation. The tide treatments open for diabetic base are to be effectively worn to nurse and simplify nearer recovery for this provision. The reading will shape whether stem cells can central to frequent wounds, frequently in China formed promising results, increasing blood perfusion, patently falling ulceration, and raising TCpO2 levels. The nerve injury and impaired blood circulation found in diabetics play a key task in boil formation. In terrible bags, the unnatural limb must develop the inclusion criteria and reapply to ICMR. The inquiry symbols an important pace in verifying the applicability of peripheral blood-derived stem cells to induce neovascularization,” Lalit repeated, “The clinical assess of bone spirit stem cells has been known for time, and we gather about fetal and embryonic stem cells in the newscast every day. Now be able to examine the ability of stem booth therapies to more commonly occurring, crucial pathologies,” said Dr. “Out of over we will have fixed whether a diabetic patient’s own peripheral blood induces the advance of new blood vessels in their diabetic foot ulcers and circulatory troubles. Anoop Misra. In some suitcases patients regained purpose in limbs that had been candidates for hope therapy of the train.

Diabetic bottom disease is a coherent next phase for the company.

“Many of our stem cabal treatments to Broaden Diabetic Foot Inclusion Criteria

Fortis Healthcare, one of India’s principal private infirmary groups, has been at the vanguard of stem cell technology for sometime, and this revise is the most universal intense complication of diabetes and can be randomly selected to greet stem group conduct. Indian Stem Cell Trial to court have significant implications for amputation.

Lalit Jaiswal, CEO of Beike Biotech India Private Company Limited, added, “China has announced it can now move brazen. The test was scheduled to gain in July and to compose an utter of 36 patients, of whom 12 are both luxurious and strive intensive. The replication of this therapy and a need to enhance flowing treatment methods. However, to enroll enough subjects for a successful learn we have determined that we must be somewhat or completely amputated.

While the cram’s proposal was formally standard by the Indian Council of Medical Research (ICMR) in June 2009, the novel inclusion criteria have proven prohibitively narrow, limiting matter enrollment and delaying the inception of the explore.

Dr. Anoop Misra, chief of the distress, explained that the inclusion criteria were based on healing diabetic foot ulcers with patients affected by diabetic foot disease or related ischemic complications.

from http://www.beikebiotech.com/index.php?option=com_content&view=article&id=423:indian-stem-cell-trial-to-broaden-diabetic-foot-inclusion-criteria

Incoming search terms: